Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
about
Structure of the human κ-opioid receptor in complex with JDTicRole of kappa-opioid receptors in stress and anxiety-related behavior.Drug withdrawal conceptualized as a stressor.New mechanisms and perspectives in nicotine withdrawalNegative affective states and cognitive impairments in nicotine dependenceNicotine dependence produces hyperalgesia: role of corticotropin-releasing factor-1 receptors (CRF1Rs) in the central amygdala (CeA).Mouse models for studying genetic influences on factors determining smoking cessation success in humans.Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticityThe clinical implications of mouse models of enhanced anxiety.Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activityRole of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid ReceptorLong-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicityMajor Depressive Disorder and Kappa Opioid Receptor Antagonists.Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats.Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats.The long-lasting effects of JDTic, a kappa opioid receptor antagonist, on the expression of ethanol-seeking behavior and the relapse drinking of female alcohol-preferring (P) ratsThe kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.The opioid receptors as targets for drug abuse medicationThe role of the dynorphin/κ opioid receptor system in anxiety.Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner.Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptakeRoles of nucleus accumbens CREB and dynorphin in dysregulation of motivation.Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine ReleaseDevelopment of κ opioid receptor antagonists.The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking.Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference.Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety testsEffects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice.4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonistPreclinical evidence of new opioid modulators for the treatment of addiction.The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.Psychiatric neural networks and neuropharmacology: Selected advances and novel implicationsThe discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.Endogenous opioid system: a promising target for future smoking cessation medications.Neuropeptide systems and new treatments for nicotine addiction.Local anesthetic lidocaine delivery system: chitosan and hyaluronic acid-modified layer-by-layer lipid nanoparticles.
P2860
Q24308048-AB794FB6-4559-4BC7-8A9C-889D424C1BC2Q26991739-36D041CD-73B3-46DD-95E9-EA5030B951BBQ26997989-71D35439-AD16-496E-959D-78882CFF7E3FQ28111991-4D0C001D-AA8F-43B5-8AAA-85F3A772347EQ30371220-1CAFBF3C-4070-4BAF-AF18-67C19A39C32AQ30419954-0F4FD8F7-7953-4C69-9D45-15CDDDAF3D64Q30432964-DE5BE767-836A-4E46-8B86-8E3C537DD28DQ30435816-8C350EB9-6A63-42BA-89DC-C4354C929BD8Q30474232-3F140CD4-35E5-4232-BF55-CEF528E4F1A2Q30474756-B0FC5FE0-49E1-4A94-BE96-FBE89D52E981Q33847097-2D6C93A5-C47B-49F9-85C6-2E691CD23A52Q33860286-C88E147C-640A-4857-B256-A0C5BDA420CAQ34285100-CEDCF590-4535-4993-99C8-B4AC2B3C4EF1Q34527874-4CD5139E-D104-45B3-A927-A95889171553Q34632744-1A24FBE8-CC01-410C-83C8-082C8BB1DF32Q35375156-C6AD9D5E-A15B-4774-95BF-19A80C300CE7Q35892525-2EB44899-02D7-4D6A-A4D6-299F3D6FA813Q35906830-E1048328-5855-4E59-A61C-660850203602Q35956317-4FB4CDC3-A0F0-4F91-B0A5-6B23F346335FQ35978068-1C8F4418-70F5-43CD-94D9-0D30187057A4Q36287728-5BE4700D-6722-4352-A3F6-1B19A5DE99CBQ36350809-621E325B-016A-4D7A-8AA5-24742A0CF5B0Q36470824-00926138-E326-4F75-B8F9-CB8C4F0506A7Q36554599-EC8B1D1D-C85C-4540-B1B8-189D349B3B0DQ36565615-CEC3A60A-1DEA-45BF-9D97-0B41E3C1FBF8Q36728154-E8DC262B-C8F4-4FC1-843D-C0263B6EA050Q36836438-893EB12F-F74B-4587-80A7-4CBC99C24598Q36900018-C321143C-C844-400B-9069-09E2EC682734Q36916404-4502EBC3-782A-4FAB-A278-1835D665FD44Q36924403-5AB59C83-F584-4952-AAE8-C9EFA4EEF70CQ37291954-6B905C08-3D61-45EE-8DF9-C9C548266370Q37483722-9913C9EC-35A9-4B48-AE8A-0F2D6174682EQ37772519-565D1642-9868-4437-81B8-23B1D19B47A6Q37946259-E1EDD08B-9098-4727-AE3C-3B935789B7D8Q38197608-E147509B-D5C8-40EE-B0BE-E707D8746F87Q38225032-B9A9A8A1-2B90-4736-8436-CF2BD0514E44Q38373652-60E7A71C-2795-439E-A651-F2370119ACD6Q38747115-381DE4BF-7949-4396-8115-05A394780C89Q39059946-F9860C42-3493-4354-9F36-548FE48B8659Q39170861-267C06BE-0887-4FFE-8BA6-2621731B6762
P2860
Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of the selective kappa- ...... , and withdrawal in the mouse.
@ast
Effect of the selective kappa- ...... , and withdrawal in the mouse.
@en
type
label
Effect of the selective kappa- ...... , and withdrawal in the mouse.
@ast
Effect of the selective kappa- ...... , and withdrawal in the mouse.
@en
prefLabel
Effect of the selective kappa- ...... , and withdrawal in the mouse.
@ast
Effect of the selective kappa- ...... , and withdrawal in the mouse.
@en
P2093
P2860
P1433
P1476
Effect of the selective kappa- ...... , and withdrawal in the mouse.
@en
P2093
Frank Ivy Carroll
K J Jackson
P2860
P2888
P304
P356
10.1007/S00213-010-1803-1
P577
2010-03-16T00:00:00Z
P5875
P6179
1042022732